Throughout the projection period, global demand for interventional cardiology devices is expected to grow at an 8.4% CAGR (2022 to 2032). The market for interventional cardiology equipment is anticipated to be worth US$ 16.4 billion in 2022 and US$ 36.9 billion by 2032.
The trajectory of interventional cardiology device adoption trends is rising as a result of the numerous benefits associated with minimally invasive surgeries, such as reduced surgical pain, injury, and faster recovery time when compared to conventional surgeries, proving to be a viable alternative to open surgery.
Demand for interventional cardiology devices is likely to drive the market throughout the forecast period, owing to manufacturers' focus on substantial R&D to provide the healthcare sector with significant solutions.
Diabetes is more likely to be associated with other illnesses that increase the risk of coronary heart disease. Diabetes and hypertension are also risk factors that drive the demand for interventional cardiology equipment.
According to the American Heart Association, by 2035, around 45% of the US population will be suffering from heart disease as a result of variables such as high obesity, excessive smoking, and unhealthy lifestyles, which may lead to heart attacks and other related difficulties.
Additionally, 1.5 million Americans are diagnosed with diabetes each year in the United States alone. Diabetes prevalence is increasing due to an increase in the senior population; it is estimated that 25% of all geriatric adults (aged 60 and over) in the United States have diabetes.
A few key players in the interventional cardiology devices market are
- Medtronic
- Boston Scientific Corporation
- Abbott
- Edward Lifesciences Corporation
- Cardinal Health
Get More Insights@ https://www.futuremarketinsights.com/reports/interventional-cardiology-devices-market
Key Segments
By Product:
- Angioplasty Balloons
- Old/Normal Balloons
- Drug-eluting Balloons
- Cutting and Scoring Balloons
- Angioplasty Stents
- Drug-eluting Stents
- Bare-mental Stents
- Bioabsorbable Stents
- Structural Heart Devices
- Aortic Valve Therapy Devices
- Other Therapy Devices
- Catheters
- Angiography Catheters
- Guiding Catheters
- IVUS/OCT Catheters
- Plaque Modification Devices
- Atherectomy Devices
- Thrombectomy Devices
- Hemodynamic Flow Alteration Devices
- Embolic Protection Devices
- Chronic Total Occlusion Devices
- Other Devices
- Guidewires
- Vascular Closure Devices
- Introducer Sheaths
- Hemostasis Valves
- Balloon Inflation Devices
According to research report the interventional cardiology devices market is expected to reach USD 20.85 billion by 2022 from USD 14.52 billion in 2017, at a CAGR of 7.5%.
Ask for Free PDF Brochure: https://www.marketsandmarkets.com/pdfdownloadNew.asp?id=548Interventional cardiology devices are devices that are used to unclog blood vessels and restore normal blood flow.
The market for these devices is expected to reach USD 20.85 billion by 2022 from USD 14.52 billion in 2017, at a CAGR of 7.5% during the forecast period.
Growth in this market is mainly driven by factors such as the rapidly increasing geriatric population and technological advancements in interventional cardiology devices.The interventional cardiology devices market is geographically segmented into North America, Europe, Asia Pacific, and the Rest of the World (RoW).
Asia Pacific is expected to register the highest growth due to the improving healthcare infrastructure, the heavy burden of cardiovascular diseases, rising healthcare expenditure, and growth in the demand for interventional cardiology devices.On the basis of type, the interventional cardiology devices market is categorized into angioplasty balloons, angioplasty stents, catheters, plaque modification devices, hemodynamic flow alteration devices, and other interventional cardiology devices.
Growth in this market is mainly due to the increasing adoption of these devices for plaque removal in arteries due to their effectiveness.The angioplasty stents market is further segmented into bare-metal stents, drug-eluting stents, and bioresorbable stents.
